



Welireg in the UAE

The MoHAP named-patient coordination pathway — indicative 2026

RARE DISEASE · VHL-ASSOCIATED TUMOURS / ADVANCED RCC

The clinical situation

Welireg (belzutifan) is an FDA-approved small-molecule HIF-2 α inhibitor from Merck for von Hippel-Lindau (VHL)-associated tumours (renal cell carcinoma, pancreatic neuroendocrine tumours, CNS haemangioblastomas) not requiring immediate surgery, and for advanced clear-cell RCC after prior systemic therapy. Taken as an oral tablet once daily. Eligibility in VHL requires genetic confirmation of VHL; in RCC, prior line history per label. Anaemia and hypoxia are on-label class effects requiring standing monitoring.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your oncologist or clinical geneticist confirms VHL genetic status or RCC line history and documents a written rationale.
- 2 Prescribing facility confirmed.** A UAE tertiary centre with haemoglobin, oxygen-saturation, and renal-function monitoring capability is identified.
- 3 MoHAP named-patient application.** Clinical rationale, genetic/imaging report, patient reference, product details, and anaemia/hypoxia surveillance plan are filed (DoH Abu Dhabi / DHA Dubai per facility).
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; ambient-controlled shipment with chain-of-custody.
- 5 Arrival & dispensing.** The hospital pharmacy releases the bottle with once-daily dosing instructions and a monitoring schedule; refills coordinated on a rolling monthly basis.

Indicative economics

Reference US cash-pay range: USD 25,000–30,000 per 30-day supply; drug-only reference. Reserve Meds provides a transparent delivered quote at intake.

Indicative first-dose timing

7–14 days from a complete MoHAP application to first dispense, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and MoHAP review including genetic attestation. **Logistics.** Chain-of-custody shipment coordination. **Concierge case lead.** Named point of contact for family (often multi-generational in VHL) and physician through intake and refills. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating oncologist or clinical geneticist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Welireg × UAE first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/welireg-uae.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team